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Background: KRAS mutation occurs in 35%-40% of colorectal cancer (CRC). The aim of our study was to evaluate
the pathological and molecular features of specific KRAS mutated colorectal carcinomas. KRAS and BRAFV600E
mutation tests were performed in 762 primary tumors from a consecutive cohort study of Chinese CRC patients.
Methods: DNA mismatch repair (MMR) status was determined by immunohistochemistry (IHC) staining. Assessment
of KRAS and BRAF V600E mutational status was performed using a multiplex allele-specific PCR-based assay.
Results: Mutations of KRAS (34.8%) and BRAFV600E (3.1%) were nearly mutually exclusive. Both KRAS- and BRAF- mutated
tumors were more likely to be located at proximal colon than wild-type (WT) carcinomas. KRAS-mutated carcinomas
were more frequently observed in female patients (47.5% vs 37.1%, p = 0.005) and mucinous differentiation (34.7% vs
24.8%, p = 0.004), but have no difference between lymph node (LN) metastases and among pTNM stages. Whereas,
BRAF-mutated carcinomas more frequently demonstrated histologic features such as proximal location (60.9% vs 20.9%,
p = 0.001), low-grade histology (43.5% vs 18.0%, p = 0.005), mucinous differentiation (69.6% vs 25.9%, p = 0.001) and
deficient MMR (dMMR) (21.7% vs 7.6%, p = 0.03). In particular, KRAS codon 12 mutated carcinomas had increased lymph
node metastasis (odds ratio [OR] = 1.31; 95% confidence interval [CI] = 1.04 to 1.65; P = 0.02) and were more likely in
higher disease stage (III-IV) than that of WT carcinomas (OR = 1.30; 95% CI = 1.03 to 1.64; P = 0.03). However, there were
no significant differences in lymph node metastasis and disease stage between KRAS codon 13 mutated carcinoma and
WT carcinoma patients.
Conclusions: In summary, KRAS codon 12 mutation, but not codon 13 mutation, is associated with lymph node
metastasis and higher tumor stages.
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Colorectal cancer (CRC) is the third most common can-
cer and the fourth leading cause of cancer mortality in
China [1]. CRC is a multistep process based on the accu-
mulation of somatic mutations and can be divided into
at least two different and seemingly independent path-
ways, which is the chromosomal instability (CIN) and
microsatellite instability (MSI) pathways [2-5]. CIN oc-
curs in about 85% patients with sporadic CRC and is
thought to originate from a relatively uniform and linear* Correspondence: jmying@hotmail.com
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unless otherwise stated.accumulation of genetic changes in APC, KRAS and
TP53 genes [6]. However, sporadic tumors with MSI-
high (MSI-H) are originated from promoter hyperme-
thylation of the MLH1 gene, more frequently found in
females, and tend to be poorly differentiated tumors, of
mucinous subtype and often harboring somatic muta-
tions in BRAFV600E [7,8]. Dysfunction of the DNA mis-
match repair (MMR) system is the main cause of MSI,
which leads to accelerated accumulation of single nu-
cleotide mutations and alterations in the length of sim-
ple, repetitive microsatellite sequences [9].
Recently, MMR status, KRAS and BRAF mutation status
have attracted remarkable attention due to their potential
prognostic and predictive role in colorectal carcinomasis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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35% to 40% of colon cancers, with roughly 2/3 of these
mutations in codon 12 and 1/3 in codon 13 [11,13]. The
presence of a KRAS mutation is predictive for resistance
to anti-EFGR monoclonal antibodies (mAbs) in advanced
colon cancer [13-16]. However, the biological and func-
tional consequences of KRAS mutations at codon 12 may
be different from those at codon 13 [17-19]. It has been
suggested that patients whose tumors harbor a KRAS
Gly13Aspmutation may benefit from anti-EGFR mAb ther-
apy [20-22]. The clinical significance of KRAS mutation in
colorectal carcinoma patients is controversial; some studies
reported no association with survival, whereas others sug-
gested that patients with KRAS mutated colorectal carcin-
oma have poorer outcome for any mutation subtype,
mutation in codon 12 only or codon 13 only [19,21,23,24].
On the other hand, BRAF is also involved in the
MAPK/ERK signaling pathway and oncogenic mutations
in this gene have been identified in CRC [25]. Several
studies have reported a range of frequencies regarding
BRAF mutations in colon cancer (7.1%–13.3%), with the
most frequent mutation being a single substitution at
nucleotide 1,799, substituting valine for glutamic acid
(V600E) [7]. Mutations in BRAF are most commonly
found in microsatellite-unstable (MSI) tumors, whereas
they are less common in microsatellite-stable (MSS) tu-
mors [10,26,27]. Mutations in KRAS and BRAF genes
seem to occur in a mutually exclusive manner, and both
are suggested as integral components for an effective
molecular classification of colorectal cancer.
More accurate prediction of outcome among patients
with CRC remains a worthy area of investigation. Al-
though the roles of MMR status, KRAS and BRAF muta-
tions on clinical outcome are frequently documented,
the accurate analysis of these 3 features on clinicopatho-
logic and prognosis with emphasis on the specific KRAS
gene mutation is still missing. The aim of this study was
to evaluate the prognostic role of MMR status, BRAF
mutations and specific KRAS point mutation in 762 pa-
tients in Chinese population, and several clinicopatho-
logic features to better stratify colorectal cancer patients.
Methods
Study population
The clinicopathological records of 762 patients with cor-
responding paraffin-embedded material available for mo-
lecular analysis were retrospectively collected from the
Department of Pathology, Cancer Institute and Hospital,
Chinese Academy of Medical Sciences, Beijing, China
from December 2011 to December 2012. Patients who
had a history of preoperative radiochemotherapy or
gastrointestinal surgical resection were excluded. Histo-
pathological criteria were reviewed and included tumor
diameter, pT and pN classification, grade of differentiation,histological subtype, tumor location, tumor size as well as
the pTNM stage. The size of each tumor was evaluated by
measuring its maximum diameter. Grading was deter-
mined according to the 2010 WHO histological classifica-
tion. The pTNM stage system of the 7th edition AJCC
cancer staging was used. Evaluating of M stage was mainly
according to confirmed pathological results and/or radio-
logical data. Location in the colon was designated as prox-
imal colon for tumors located in the cecum, ascending
colon and transverse colon, and as distal colon for tumors
in the descending colon and sigmoid colon. Mucinous dif-
ferentiation in the tumor was defined by the presence of
pools of extracellular mucin-containing clusters of carcin-
omatous cells. When >50% of analyzed tumor demon-
strated mucinous differentiation, the tumor was classified
as mucinous carcinoma. The study was approved by the
Institute Review Board of the Cancer Hospital, CICAMS.
Each participant signed an Institutional Review Board ap-
proved informed consent in accordance with current
guidelines.
KRAS and BRAFV600E mutation analysis
Assessment of KRAS and BRAF V600E mutational status
was performed in the Molecular Pathology Laboratory
of Department of Pathology, CICAMS, using appropriate
quality control procedures. Mutation status was deter-
mined using genomic DNA extracted from macrodis-
sected formalin-fixed, paraffin-embedded tumor tissue.
Both KRAS (codons 12 and 13) and BRAF (p.V600E) muta-
tion tests were performed using a multiplex allele-specific
PCR-based assay (ACCB, Beijing, China), together with the
Stratagene Mx3000P (Agilent Technologies Inc, Santa
Clara, CA), which assesses seven different potential muta-
tions in KRAS codons 12 and 13 (Gly12Ala, Gly12Asp,
Gly12Arg, Gly12Cys, Gly12Ser, Gly12Val, and Gly13Asp).
Neither KRAS nor BRAFV600E mutated tumors were desig-
nated as WTcarcinomas.
DNA mismatch repair proteins expression
A panel of four-antibody of MMR proteins was per-
formed as a routine practice in our pathological depart-
ment, contained MLH1, PMS2, MSH2 and MSH6. All of
the 762 samples were stained in an autostainer (Autostai-
ner Link 48, Dako, Denmark). Primary mouse monoclonal
antibodies included MLH1 antibody (ES05, Dako), MSH2
antibody (FE11, Dako). Primary rabbit monoclonal anti-
bodies included MSH6 antibody (EP49, Dako) and PMS2
antibody (EP51, Dako). Carcinomas were considered as
deficient MMR (dMMR) when there was a completely
absent staining of a detectable nuclear signal in neoplas-
tic cells for at least one protein. While the adjacent nor-
mal mucosa or stromal/lymphoid cells that showed
presence of nuclear staining are regarded as internal
positive control.
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The primary objective of this study was to identify dis-
tinct clinicopathologic features associated with specific
KRAS and BRAFV600E mutation status. Differences of pa-
tient characteristics and clinicopathologic factors in the
two-dimensional cross-comparison were evaluated sta-
tistically by Pearson’s χ2-test or Fischer’s exact test. Stat-
istical tests were two-sided, and P < 0.05 were considered
significant. Logistic regression models were used to detect
associations of these characteristics with each of the spe-
cific KRAS mutations and provided estimates of odds ratio
(ORs) and confidence intervals (CIs). Statistics were
carried out using SPSS software (version 16.0 of SPSS,
Chicago, IL, USA).
Results
Primary samples from 762 colorectal carcinoma patients
were analyzed for KRAS, BRAF gene mutations and
MMR status. Mutations of KRAS occurred in 34.8% of
colorectal carcinomas. BRAFV600E mutation was demon-
strated in 3.1% of colorectal carcinomas. There was one
tumor demonstrating mutations in both KRAS and
BRAF; this case was excluded from the analysis. Mutated
carcinomas were compared with non mutated carcin-
omas for sex, age, histological features and molecular
characteristics (Table 1). In addition, given that non-
KRAS-mutated tumors include a distinct subset character-
ized by BRAF mutation, analyses were also performed to
compare KRAS-mutated tumors with both BRAF-mutated
tumors and the remaining subset of colorectal carcinomas,
with observed neither somatic oncogene mutation.
Clinical information and morphological characteristics
The mean age at presentation for KRAS-mutated carcin-
oma was 57.7 ± 11.3 years, which was no significantly
different to that for non-mutated-KRAS carcinoma at
57.3 ± 11.5 years and WT carcinoma cases at 57.1 ±
11.5 years. Furthermore, regarding the age, there was no
significant difference in younger (<45) and older (≥45)
patients among KRAS-mutated, KRAS-wild type and
BRAF-mutated carcinomas.
Gender distribution did not differ significantly be-
tween BRAF-mutated colorectal carcinomas. However,
female patients were more likely to possess KRAS muta-
tion than males (47.7% vs 37.1%, P = 0.004). BRAF-mu-
tated carcinomas were more likely to be found in
proximal colon than wild-type BRAF tumors (60.9% vs
20.9%, P < 0.0001). In addition, compared with KRAS-wild
type carcinomas, KRAS-mutated carcinomas were more
likely located in proximal colon (28.3% vs 18.7%, P =
0.004). Twenty five subjects had synchronous carcinomas
in both proximal colon and rectum, including 6 KRAS-
mutated and 19 KRAS-wild type carcinoma. However,
there was no synchronous carcinoma found in BRAF-mutated patients in our study. In addition, BRAF-mutated
carcinomas were significantly associated with larger tumor
size compared with wild-type BRAF tumors (5.83 ± 2.13 vs
4.87 ± 1.89; P = 0.004).
Both BRAF- and KRAS-mutated carcinomas demon-
strated more frequently mucinous differentiation when
compared with BRAF- and KRAS- wild type carcinomas
respectively (34.7% vs 24.8% and 69.6% vs 25.9%; P =
0.004 for KRAS-mutated carcinomas vs KRAS-wild type
carcinomas; P < 0.0001 for BRAF-mutated carcinomas vs
BRAF-wild type carcinomas). BRAF-mutated carcinomas
were observed with higher tumor grade (G3) than
BRAF-wild type carcinomas (43.5% vs 18.0%; P = 0.005),
however, this did not differ significantly with KRAS-mu-
tated and -wild type carcinomas. In addition, there were
no significantly difference in aspects of pT stage, pN
stage and disease stage among KRAS-mutated, BRAF-
mutated and wild type carcinomas.
Differences with specific KRAS mutations in CRC
The distribution and frequencies of the various tumor
and clinicopathological characteristics of specific KRAS
mutation were summarized in Table 2. Mutation fre-
quencies at codon 12 and codon 13 were 26.9% (205/
761) and 7.9% (60/761), respectively. The most common
variant in codon 12 was the p.G12D/A mutation (101/
265, 38.1%), followed by the p.G12V mutation (64/265,
24.2%). The p.G13/D mutation frequency was 22.6% (60/
265). There was no gender preponderance between
codon 13 mutation and WT carcinoma patients. How-
ever, female patients were more likely to carry codon 12
mutations than WT carcinoma cases (47.8% vs 36.4%;
OR = 1.38; 95% CI = 1.10 to 1.74; P = 0.005). Codon 12
and 13 mutated carcinomas were more likely to be
found in the proximal location than WT carcinomas re-
spectively (Codon 12: 29.1% vs 16.7%; OR = 3.17; 95%
CI = 2.24 to 4.49; P < 0.0001. Codon 13: 25.0% vs 16.7%;
OR = 3.37; 95% CI = 1.67 to 6.82; P < 0.0001). Both
codon 12 and codon 13 mutated carcinomas demon-
strated more frequently mucinous differentiation when
compared with WT carcinomas (Codon 12: 33.7% vs
21.1%; OR = 1.53; 95% CI = 1.21 to 1.93; P = 0.001;
Codon 13: 36.7% vs 21.1%; OR = 1.95; 95% CI = 1.20 to
3.17; P = 0.001).
Univariate logistic regression models identified the fol-
lowing factors as statistically significantly between KRAS
codon 12 mutated carcinomas and WTcarcinomas: gender,
pN stage, pTNM stage and histological subtype (Figure 1A).
In particular, codon 12 mutated carcinomas had increased
lymph node metastasis (pN stage) than WT carcinomas
(55.6% vs 45.9%; OR = 1.31; 95% CI = 1.04 to 1.65; P = 0.02).
Moreover, codon 12 mutated carcinomas were more likely
in higher disease stages (III-IV) than that of WT carcin-
omas (56.1% vs 46.7%; OR = 1.30; 95% CI = 1.03 to 1.64;
Table 1 Distributions of clinicopathologic characteristics by KRAS and BRAF mutation status
Characterics
Mutant KRAS Wild-type KRAS
P-value
Mutant BRAF Wild-type BRAF
P-value
(n = 265) (n = 496) (n = 23) (n = 738)
Sex 0.005 0.26
Male 139 (52.5%) 312 (62.9%) 11 (47.8%) 440 (59.6%)
Female 126 (47.5%) 184 (37.1%) 12 (52.2%) 298 (40.4%)
Tumor location 0.004 <0.0001
Proximal colon 73 (28.3%) 90 (18.7%) 14 (60.9%) 149 (20.9%)
Distal colon 52 (20.2%) 135 (28.0%) 5 (21.7%) 178 (25.0%)
Rectum 133 (51.5%) 257 (53.3%) 4 (17.4%) 386 (54.1%)
pT stage 0.39 0.35‡
pT1-2 31 (11.7%) 69 (13.9%) 1 (4.3%) 98 (13.3%)
pT3-4 234 (88.3%) 427 (86.1%) 22 (95.7%) 640 (86.7%)
pN stage 0.09 0.11
pN0 124 (46.8%) 264 (53.2%) 8 (34.8%) 380 (51.5%)
pN1-2 141 (53.2%) 232 (46.8%) 15 (65.2%) 358 (48.5%)
Disease stage 0.10 0.13
I-II 123 (46.2%) 260 (52.4%) 8 (34.8%) 374 (50.7%)
III-IV 143 (53.8%) 236 (47.6%) 15 (65.2%) 364 (49.3%)
Tumor grade 0.26 0.005‡
G1-2 221 (83.4%) 397 (80.0%) 13 (56.5%) 605 (82.0%)
G3 44 (16.6%) 99 (20.0%) 10 (43.5%) 133 (18.0%)
Histological type 0.004 <0.0001‡
Mucinous 92 (34.7%) 123 (24.8%) 16 (69.6%) 191 (25.9%)
Ohter 173 (65.3%) 373 (75.2%) 7 (30.4%) 547 (74.1%)
MMR status 0.76 0.03§
Proficient 243 (91.7%) 458 (92.3%) 18 (78.3%) 682 (92.4%)
Deficient 22 (8.3%) 38 (7.7%) 5 (21.7%) 56 (7.6%)
Age, y 0.65† 0.35†
Mean (SD) 57.7 ± 11.3 57.3 ± 11.5 59.6 ± 10.1 57.3 ± 11.4
Median 58.5 58.0 59.0 58.0
Range 27.0-84.0 21.0-87.0 38.0-82.0 21.0-87.0
Age,y 0.95 0.23‡
<45 37 (14.0%) 70 (14.1%) 1 (4.3%) 105 (14.2%)
≥45 228 (86.0%) 426 (85.9%) 22 (95.7%) 633 (85.8%)
Tumor size (cm) 0.68† 0.004†
Mean (SD) 4.95 ± 2.08 4.89 ± 1.81 5.83 ± 2.13 4.87 ± 1.89
Median 4.5 4.5 6 4.5
Range 1.5-17.0 1.0-14.0 3.0-11.0 1.0-17.0
Tumor size 0.32 0.09
<4.5 cm 121 (45.7%) 208 (41.9%) 6 (26.1%) 322 (43.6%)
≥4.5 cm 144 (54.3%) 288 (58.1%) 17 (73.9%) 416 (56.4%)
Abbreviations: MMR mismatch repair, SD standard deviation.
†Two-sided Kruskal Wallis test.
‡Two-sided χ2 test with continuity correction.
§Fischer’s exact test.
Others are two-sided χ2 test.
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Table 2 Distributions of clinicopathologic characteristics by KRAS codon 12 and codon 13 mutation
Characterics Mutant KRAS Codon 12 Null carcinoma P-value
(Codon 12 vs Null)
Mutant KRAS Codon 13 P value
(Codon 13 vs Null)(n = 205) (n = 473) (n = 60)
Sex 0.005 0.12
Male 107 (52.2%) 301 (63.6%) 32 (53.3%)
Female 98 (47.8%) 172 (36.4%) 28 (46.7%)
Tumor location <0.0001 <0.0001
Proximal colon 58 (29.1%) 76 (16.7%) 15 (25.0%)
Distal colon 40 (20.1%) 253 (55.7%) 13 (21.7%)
Rectum 101 (50.8%) 125 (27.6%) 32 (53.3%)
pT stage 0.20 0.89
pT1-2 22 (10.7%) 68 (14.4%) 9 (15.0%)
pT3-4 183 (89.3%) 405 (85.6%) 51 (85.0%)
pN stage 0.02 0.90
pN0 91 (44.4%) 256 (54.1%) 33 (55.0%)
pN1-2 114 (55.6%) 217 (45.9%) 27 (45.0%)
Disease stage 0.03 0.99
I-II 90 (43.9%) 252 (53.3%) 32 (53.3%)
III-IV 115 (56.1%) 221 (46.7%) 28 (46.7%)
Tumor grade 0.14 0.26‡
G1-2 176 (85.9%) 384 (81.2%) 45 (75.0%)
G3 29 (14.1%) 89 (18.8%) 15 (25.0%)
Histological type 0.001 0.007
Mucinous 69 (33.7%) 100 (21.1%) 22 (36.7%)
Ohter 136 (66.3%) 373 (78.9%) 38 (63.3%)
MMR status 0.87 0.30‡
Proficient 190 (92.7%) 440 (93.0%) 53 (88.3%)
Deficient 15 (7.3%) 33 (7.0%) 7 (11.7%)
Age, y 0.59† 0.47†
Mean (SD) 57.6 ± 11.4 57.1 ± 11.5 58.3 ± 10.6
Median 59.0 58.0 57.5
Range 27.0-84.0 21.0-87.0 31.0-77.0
Age,y 0.86 0.09
<45 31 (15.1%) 69 (14.6%) 4 (6.7%)
≥45 174 (84.9%) 404 (85.4%) 56 (93.3%)
Tumor size (cm) 0.27 0.96
Mean (SD) 4.99 ± 2.13 4.82 ± 1.76 4.83 ± 1.92
Median 4.5 4.5 4.4
Range 1.5-17.0 1.0-14.0 3.5-12.0
Tumor size 0.77 0.28
<4.5 cm 90 (43.9%) 202 (42.7%) 30 (50.0%)
≥4.5 cm 115 (56.1%) 271 (57.3%) 30 (50.0%)
Abbreviations: MMR mismatch repair, SD standard deviation, Null neither KRAS nor BRAFV600E mutation.
†Two-sided Kruskal Wallis test.
‡Two-sided χ2 test with continuity correction.
Others are two-sided χ2 test.
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Figure 1 Forest plot of univariate logistic model associations with KRAS codon 12 mutation status (A) and codon 13 mutation status (B). P values
are for two-sided Pearson χ2 test. CI = confidence interval; dMMR = deficient mismatch repair; LCL = lower confidence limit; UCL = upper confidence
limit; OR = odds ratio.
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ferences in lymph node metastasis and disease stage be-
tween codon 13 mutated carcinomas and WT carcinoma
patients (Figure 1B). In addition, KRAS mutated carcin-
omas demonstrated no differences in tumor invasion depth
(pT stage) with WT carcinomas in both codon 12 and 13
mutated cases.
Discussion
To the best of our knowledge, this is the first study to
demonstrate that patients with KRAS codon 12 mutated
colorectal carcinomas had a more advanced tumor stage
than those with tumors harboring p.G13D mutation or
wild-type KRAS in a large cohort of Chinese population.
In addition, the KRAS codon 12 mutated carcinomas in
our study also displayed morphologic features typically
associated with adverse behavior regardless of tumor lo-
cation. Our data are consistent with previous reports,indicating that the presence of a mutation in KRAS
codon 12 confers substantially greater oncogenic poten-
tial than codon 13 mutation [18,20,28-30].
The incidence of KRAS mutation in our reports was
approximately 34.8%, which is similar to that described
in other studies. However, the frequency of BRAFV600E
mutation was 3.1%, which is lower than in studies of
western countries, but similar to that of Asian populations
[27,31-33]. This indicates that ethnicity and/or environ-
mental factors might contribute to the discrepancy. Unlike
reports from Caucasians, patients with BRAFV600E mu-
tated tumors in our study did not differ significantly in as-
pects of sex and age [10]. KRAS mutated cases were more
likely to be female patients but with no significant differ-
ence in age distribution. Several studies reported that
BRAFV600E mutated tumors were more likely to have a
more aggressive biology with four or more positive lymph
nodes and higher pTNM stage in large population-based
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consistent with our results, which presented that mutation
in either BRAFV600E or KRAS was not related to the ad-
verse clinicopathological features accompanied by ad-
vanced lymph node metastasis and III-IV disease stages.
Admittedly, this difference may be related to our smaller
size of the BRAFV600E mutation subgroup. However, both
BRAFV600E and KRAS mutated carcinomas were more
likely to be located in the proximal colon and mucinous
carcinomas. In addition, MMR deficient status was less
likely to be associated with KRAS mutations, but have a
positive correlation with BRAFV600E mutations [10,35].
Goldstein J, et al. reported that BRAFV600E mutation is a
poor prognostic factor in metastatic MSI-H colorectal
tumors [38].
To our knowledge based on the literature search in
Pubmed, this is the first study to address the clinico-
pathological difference between KRAS codon 12 and 13
mutations in over 500 of BRAF-wild type colorectal can-
cers in Chinese population [39-41]. Although several
previous studies had distinguished the difference be-
tween the prognostic associations of KRAS mutations in
codon 12 and 13, none of the large studies (with a sam-
ple size more than 300) controlled for BRAF mutation
status in their analyses, and results were conflicting
[12,24,42,43]. The initial studies considered both muta-
tions including codon 12 and 13 as a whole to analyze
the clinicopathological features and disease outcome.
Only small and very recent detailed reports assessed the
effect of KRAS mutations where the codon 12 and 13
were analyzed separately [18,19,21]. RASCAL study, the
initial data from clinical trials, suggested that KRAS mu-
tation status is an important prognostic factor for pro-
gression and outcome in the CRC patients and glycine
to valine in codon 12 convey a more aggressive bio-
logical manner [22,43,44]. The results have been broadly
accepted all over the world except that the patients en-
rolled in the study were distributed over 21 different
countries and the results may be confounded with the
different ethnic and environmental factors.
In our study, compared with WT carcinoma cases,
both KRAS codon 12 and codon 13 mutations were as-
sociated with proximal (vs distal) tumor site of the
colon. The distribution of KRAS codon 12 and 13 muta-
tions did not differ considerably by tumor subsite , con-
sistent with findings from other reports [19]. Besides,
proximal colon carcinomas were more likely than distal
carcinomas to be KRAS-mutated and BRAF-mutated.
Rosty. C, et al. reported that both KRAS- and BRAF-mu-
tated carcinomas more frequently demonstrated focal or
predominant mucinous differentiation than WT carcin-
omas, which was consistent with our findings [11]. In
addition, mucinous tumors were more likely than other
type of colorectal carcinomas in either KRAS codon 12or 13 mutated tumors. Mucinous colonic adenocarcin-
oma is a frequently encountered histologic subtype of
colorectal tumors, which is often associated with worse
clinical outcome and decreased overall survival [45,46].
The most valuable finding of this study is that KRAS
codon 12 mutated tumors demonstrated more positive
lymph nodes and pTNM III-IV stage of disease than
WT carcinoma patients, whereas tumors with codon 13
mutation did not differ by number of positive lymph
nodes or pTNM stage. This was consistent with findings
from a smaller report, which KRAS codon 12 mutation
was found to be linked with more aggressive clinicopath-
ological features and worse clinical outcomes [19,47].
Mutations in codons 12 and 13 lead to alterations in
encoded amino acids adjacent to the GTP binding
pocket and reduced the GTPase activity of KRAS protein
after guanine nucleotide activating protein (GAP) bind-
ing [17,48-50]. Subsequently, these conformational and
structural changes of the EGFR signaling pathway are
out of control with constitutive activation of KRAS pro-
tein. Nonetheless, theses structural modifications will be
different in case of each codon and the amino acid chan-
ged conferring variable activated KRAS effects. In par-
ticular, in vitro and in vivo studies indicate that KRAS
codon 12 mutations have greater transforming capacity
when compared with codon 13 mutations [23,51,52]. On
the basis of protein computational analysis, codon 12-
mutated KRAS remains in an active GTP-bound state lon-
ger than codon 13-mutated or wild type KRAS. It seems
that mutations in codon 13 share the similar protein con-
firmation with wild type KRAS [53]. Consequently, codon
13 mutations confer reduced transforming ability in colon
tumor cells.
Despite these positive findings, our study had some
limitations. First, because our study lacked data on
tumor CIMP (Cpg Island Methylator Phenotype) status
and cause of dMMR status, we could not distinguish the
correlations of somatic and germline mismatch repair
mutations with KRAS and BRAF mutations. Second, al-
though based on a large population size, the low inci-
dences of BRAF mutation (3.1%) made the subgroups
relatively small and further validations with more popu-
lation are needed. Finally, we did not examine other less
common mutations in KRAS codons 61, 117 and 146,
which are also the negative predictive marker for re-
sponse to anti-EGFR therapy [54].
Conclusions
In conclusion, our study suggests that specific epidemio-
logic and clinicopathologic characteristics were associ-
ated with KRAS and BRAFV600E mutations in a large
cohort of Chinese colorectal carcinoma population. Spe-
cifically, tumor size of 6 cm or longer, low-grade hist-
ology, and dMMR status were associated with a higher
Li et al. BMC Cancer  (2015) 15:340 Page 8 of 9incidence of BRAFV600E-mutated tumors. Both muta-
tions tend to be proximal tumor location and mucinous
histology, but KRAS-mutated tumors are more common
in female patients. Finally, KRAS codon 12 mutation,
but not codon 13 mutation, is associated with more
positive lymph nodes and higher pTNM stages. Because of
its correlation with a more advanced stage, patients with
KRAS codon 12 mutations may have worse survival than
those with KARS 13 mutations or wild-type KRAS. Further
studies need to define the mechanism by the clinicopatho-
logic and epidemiologic characteristics that may explain
the association with these specific mutations.
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